Sorry, you need to enable JavaScript to visit this website.
Skip to main content
This promotional website is developed and funded by Gilead Sciences Ltd and intended for healthcare professionals in Great Britain.
This promotional website is developed and funded by Gilead Sciences Ltd and intended for healthcare professionals in the UK and Ireland.
Report adverse events
With improvements in ART efficacy, tolerability and access in recent years, the management of HIV has evolved from treating progressive HIV infection and declining immune function to dealing with a lifelong condition in an ageing population with potential comorbidities.1,2

 

Regular screening for common comorbidities in an ageing population is essential as they can occur earlier in people living with HIV than in HIV-negative individuals. Most comorbidities are not specific to HIV itself but are associated with ageing. These include:1-3

 

• Cardiovascular disease (CVD)

• Neurological disease

• Anaemia

• Osteoporosis

• Liver disease

• Renal disease

• Frailty

• Mental illnesses

• Many non-AIDS-related cancers

• Chronic lung disease

• Type 2 diabetes

• Non-AIDS-associated infections

 

 

Managing comorbidities as a multidisciplinary team

 

Screening and treatment are usually no different than that for HIV-negative individuals, although screening may be initiated at a younger age for some age-related conditions.2 A multidisciplinary approach, with relevant expertise from specialist colleagues, should be considered when managing multiple comorbidities in people living with HIV.4,5

 

Healthcare professionals who are unfamiliar with antiretroviral therapy (ART) should seek guidance from HIV specialists before any new treatment is prescribed, as certain medications may invoke adverse drug–drug interactions.3 In situations where people living with HIV are seeing multiple HCPs, some level of shared-care arrangement is likely to be beneficial.6

 

 

A healthy lifestyle could make the difference

 

Lifestyle changes can help to decrease the risk of developing a comorbidity and reduce the impact of existing comorbidities. This may involve improvements to diet, giving up smoking or introducing an exercise regime.3,7

 

Agreement about the best course of action with realistic goals can be facilitated with other members of the care team, including dietitians. The key to successful lifestyle changes is empowerment of the central figure in the process – the person living with HIV.

 

 

Benefits of smoking cessation intervention

 

The smoking rate in people living with HIV is two to three times higher than in the general population. People living with HIV who smoke face higher non-AIDS-related mortality compared with non-smoking people living with HIV. People living with HIV who smoke may also face an increased risk of death from CVD and cancer compared with non-smoking people living with HIV, as well as an increased risk of other non-AIDS-related death.8

 

By addressing the risks associated with smoking, discussing how it may affect chances of successful treatment and the benefits of quitting to overall health, non-smoking people living with HIV may feel encouraged to quit, even more so if they are already considering stopping.

 

 

Understanding the existing comorbidities in people living with HIV or potential comorbidities associated with ageing, can inform treatment decisions include what ART regimen to initiate and what adherence strategies to implement.

You might also like

Striving towards health equalities in HIV care

Watch as experts from various sectors discuss approaches to address health inequalities in HIV care

Starting treatment

Explore the data supporting early initiation of antiretroviral therapy for HIV

Rethinking mental health in HIV

Find out more about the importance of mental health in people living with HIV and how rethinking mental health conversations can support them

References:

  1. Deeks SG, Lewin SR and Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013 Nov 2;382(9903):1525-33.
  2. Wing EJ. HIV and aging. Int J Infect Dis. 2016 Dec;53:61-68.
  3. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. 2021. Available at:https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines. Accessed October 2023.
  4. Rockstroh J, Guaraldi G and Deray G. HIV and the body: a review of multidisciplinary management. HIV Med. 2010 Sep;11 Suppl 2:1-8.
  5. Allavena C, Hanf M, Rey D et al. Antiretroviral exposure and comorbidities in an aging HIVinfected population: The challenge of geriatric patients. PLoS One. 2018 Sep 21;13(9):e0203895.
  6. Lorenc A, Ananthavarathan P, Lorigan J et al. The prevalence of comorbidities among people living with HIV in Brent: a diverse London Borough. London J Prim Care (Abingdon). 2014;6(4):84-90.
  7. European AIDS Clinical Society. EACS Guidelines v10.1. 2020. Available at:https://eacs.sanfordguide.com/. Accessed October 2023.
  8. Giles ML, Gartner C and Boyd MA. Smoking and HIV: what are the risks and what harm reduction strategies do we have at our disposal? AIDS Res Ther. 2018 Dec 12;15(1):26.

UK-BVY-0705 Date of preparation October 2023